ADVERTISEMENT
Podcasts
Treatment Shows Disease-free Survival Benefit in Patients With NSCLC
Julie Gould
Maria Asimopoulos
11/09/2021
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to best supportive care in patients with non-small cell lung cancer that had already received first line chemotherapy.
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 21
Issue 2
Advertisement
Advertisement
What's Trending?
Subscribe to our eNewsletters!
First Report Managed Care Newsletter